Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II
A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bruxelles - Brussel, Belgium, 1000
-
Genk, Belgium, 3600
-
Leuven, Belgium, 3000
-
Liege, Belgium, 4000
-
Roeselare, Belgium, 8800
-
-
-
-
-
La Rochelle, France, 17000
-
Lille, France, 59000
-
Lyon, France, 69000
-
Marseille, France, 13009
-
Marseille, France, 13275
-
Mont-de-marsan, France, 40000
-
Paris, France, 75009
-
Toulouse, France, 31000
-
-
-
-
Hamburg / 287
-
Hamburg, Hamburg / 287, Germany, 20251
-
Hamburg, Hamburg / 287, Germany, 20354
-
Hamburg, Hamburg / 287, Germany, 22177
-
-
Niedersachsen / 291
-
Hannover, Niedersachsen / 291, Germany, 30625
-
-
Nordrhein-Westfalen / 325
-
Brühl, Nordrhein-Westfalen / 325, Germany, 50321
-
-
Nordrhein-Westfalen / 481
-
Mülheim, Nordrhein-Westfalen / 481, Germany, 45468
-
-
Nordrhein-Westfalen / 616
-
Wuppertal, Nordrhein-Westfalen / 616, Germany, 42103
-
-
Sachsen / 313
-
Bautzen, Sachsen / 313, Germany, 02625
-
Dresden, Sachsen / 313, Germany, 01129
-
Leipzig, Sachsen / 313, Germany, 04105
-
Leisnig, Sachsen / 313, Germany, 04703
-
Meißen, Sachsen / 313, Germany, 01662
-
-
Schleswig-Holstein / 306
-
Wahlstedt, Schleswig-Holstein / 306, Germany, 23812
-
-
-
-
-
Bergamo, Italy, 24128
-
Firenze, Italy, 50139
-
Milano, Italy, 20132
-
Napoli, Italy, 80131
-
Roma, Italy, 00155
-
-
-
-
-
Arnhem, Netherlands, 6836 BH
-
Deventer, Netherlands, 7415 EH
-
Enschede, Netherlands, 7511 JX
-
Nijverdal, Netherlands, 7442 LS
-
-
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9324
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2090
-
-
Kwa Zulu-Natal
-
Newcastle, Kwa Zulu-Natal, South Africa, 2940
-
-
KwaZulu Natal
-
Durban, KwaZulu Natal, South Africa, 4091
-
Durban, KwaZulu Natal, South Africa, 4037
-
-
-
-
-
Alicante, Spain, 03010
-
Barcelona, Spain, 08034
-
Valencia, Spain, 46010
-
-
Barcelona
-
La Roca del Vallès, Barcelona, Spain, 08430
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08025
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36211
-
-
Tenerife
-
La Laguna, Tenerife, Spain, 38320
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males 18 to 64 years
- Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance)
- Stable heterosexual relationship for more than 6 months
- The subject must make at least four attempts at sexual intercourse
- Documented, dated, written Informed Consent Inclusion Criteria Partner
- Females 18 years, and older
- Stable, heterosexual relationship for more than 6 months with male ED subject
- Documented, dated, written Informed Consent
- Motivated to support treatment for male partner's ED
- Absence of significant sexual dysfunction as assessed by the total score on the FSFI16 > 23.55
Exclusion Criteria:
- Any unstable medical condition or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study
- Subjects who are taking nitrates or nitric oxide donors
- Subjects who are taking the following inhibitors of cytochrome P 450 CYP 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents traconazole and ketoconazole (topical forms are allowed) or erythromycin
- Known hypersensitivity to vardenafil
- Presence of significant penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease)
- History of retinitis pigmentosa
- Unstable angina pectoris
- Severe chronic or acute liver disease
- Premature ejaculator (defined as IELT < 2 minutes)
- Subjects who were taking alpha blockers
- Lost of vision of one eye because of NAION Exclusion Criteria Partner
- Presence of sexual dysfunction as assessed by the FSFI16 < 23.55
- Any unstable medical condition or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the partner's ability to complete the study or precludes the partner's participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
|
|
|
Placebo Comparator: Arm 2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo
Time Frame: 24 weeks
|
24 weeks
|
|
Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo
Time Frame: 24 weeks
|
24 weeks
|
|
Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20)
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12146
- EudraCT 2006-001228-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.